The in vitro incubation of human sickle cell erythrocytes (SS RBCs) with sodium cyanate results in significant prolongation of their 'Cr intravascular survival (1, 2) . This effect appears to be mediated through carbamylation of the amino terminal valine residue in the hemoglobin S molecule which results in inhibition of erythrocyte sickling (3). Initial clinical studies have shown that the oral administration of sodium cyanate to patients with homozygous sickle cell disease also increases erythrocyte survival and leads to improvement in anemia (4, 5). Sickle cell crises, however, continue to occur in the cyanate treated patients (5). This observation raises serious questions regarding the effectiveness of cyanate treatment in the prevention of localized intravascular sickling, and in the overall clinical management of patients with sickle cell disease.
MATERIALS AND METHODS
The blood from 4 patients with homozygous sickle cell anemia was studied. None of the patients had been transfused for at least 2 mo prior to this study. Their ages were 1, 22, 23, and 33 yr. Each patient had from 87.5 to 93.4% S hemoglobin as determined by acrylamide gel electrophoresis and hematocrit values ranging from 20 to 30%.
Four milliliters of venous blood from each patient was added to 1 ml of sterile acid-citrate-dextrose solution and separated into 2 equal portions. Both were centrifuged and the supernatant plasmas were removed. The packed red cells in one tube were made up to the original volume with a solution of sodium cyanate2 in normal saline so that the final cyanate concentration was 50 mM. The other tube of packed red cells was made up to volume with normal saline instead of cyanate. Oxygen was bubbled through the red cell suspensions for a period of 3-5 min.
Sodium 5"Chromate3 (50tiCi/ml blood) was then added to each sample, and the mixtures were incubated at 370C for 90 min with frequent swirling. The erythrocyte suspensions were washed three times with normal saline in order to remove unbound chromium and cyanate. Normal saline was added to bring the final hematocrit to 30-33%. The degree of amino terminal valine carbamylation achieved in the cyanated sample was 2.0 cyanate residues per mole of hemoglobin tetramer. 4 Erythrocytes from 3 control individuals with A hemoglobin (AA RBCs) were processed both with and without cyanate incubation in exactly the same manner as was the blood from the patients with sickle cell disease.
Erythrocyte survival studies were performed in adult, male Sprague-Dawley rats weighing between 150 to 250 g. Each animal was prepared for the transfusion study according to a technique which has been previously described (7) . Briefly, the method involves tail vein injection of a suspension of ethyl palmitate in a dose of 3 g/kg approximately 12-24 hr before the red cell survival study. A second tail vein injection with 10 units of CVF was given about 30 min before the study. The 51Cr tagged human erythrocyte suspension (1 ml/kg of packed cells) was injected in the animals through the dorsal vein of the penis. Fifteen minutes later, and at intervals of 30 min to 1 hr thereafter, 10 FAl capillary blood samples were taken from the tip of the tail for radioassay in a well-type scintillation counter. The radioactive counts for each animal were normalized and plotted on semilog paper in order to determine erythrocyte half-time (T-1) survival. The radioactivity from the first sample was defined as the 100% value. A total of 26 rats were used for these experiments.
Each patient study usually involved simultaneous determination of SS erythrocyte survival in 4 rats. Two animals were injected with cyanate treated SS RBCs and the other 2 
DISCUSSION
The results of the carbamylated SS RBC survival studies in this rat model are similar to those which have been reported for studies performed in human subjects ( 1, 2, 4, 5) . In both species, the in vitro treatment of SS RBCs with cyanate results in improvement of their survival to the extent that the blood T-1 values approach those for untreated AA RBCs. Since the effect of carbamylation is probably limited to the inhibition of sickling, one can conclude that the shortened survival of SS RBCs in the rat in room air probably relates to continuous erythrocyte sickling in areas in the body with low oxygen concentration. This hypothesis is further strengthened by the fact that exposure of the animals to 100% 02 during an SS RBC transfusion study also improves SS RBC survival (7) . The period of observation during which the animals were breathing 100% O. was too short (2 hr), however, to accurately compare the effect of hyperoxygenation alone vs cyanate alone on the survival of SS RBCs.
The degree of hemoglobin carbamylation achieved in our studies is well within the range which has been effective in prolonging SS RBC survival in man (1, 2, 5) . Partial correction of hemolytic anemia in patients with sickle cell disease has been achieved with maintenance of a minimum of 0.3 residues of cyanate per mole of hemoglobin (4, 5) . The foregoing considerations and our previous observations (7) strongly suggest that in homozygous sickle cell disease there are at least two populations of erythrocytes in terms of their survival characteristics in the rat model. One population of cells is exquisitely sensitive to changes in O. tension so that they accumulate in the blood of animals breathing 100% 02 and are rapidly removed from circulation following hypoxia. The second population is also abnormal since it has a shortened survival but differs from the first population in that hypoxia does not seem to accelerate their removal from circulation. Cyanate appears to increase the intravascular survival of both populations but does not seem to prevent the accelerated removal of the SS RBCs most sensitive to oxygen changes during the initial period of oxygen deprivation.
The overall interpretation of these results is guarded in terms of their extrapolation to man. The rat model is extremely sensitive to sickling (preliminary studies suggest that the survival of RBCs of patients with sickle cell trait is somewhat shorter than that of AA RBCs) and may actually overemphasize the response of human SS RBCs to hypoxia. On the other hand, if an antisickling agent such as cyanate fails to improve or prevent the accelerated loss of SS RBCs in the rat model during hypoxia, one might seriously question the effectiveness of that agent in other species during a comparable challenge.
The similarities between the results obtained with carbamylated human SS RBCs in the rat model and in man provide some additional evidence for the potential usefulness of this model in the study of sickle cell disease and the efficacy of various therapeutic agents.
SUMMARY
The 5"Cr survival characteristics of cyanate-treated erythrocytes from four patients with sickle cell anemia were studied in rats which had been pretreated with ethyl palmitate and a cobra venom factor. Cyanate-treated sickle cells showed significant improvement in their survival characteristics in room air. Carbamylation, however, did not prevent the accelerated loss of sickle cells from the rat's circulation following exposure to hypoxia. In a single experiment 14C-cyanate was used both as an erythrocyte label and carbamylating agent. The drop in 14C activity following exposure to hypoxia was of the same magnitude as that observed with noncarbamylated 51Cr-labeled sickle cells. These findings suggest heterogeneity for human sickle erythrocytes in the rat model in terms of their sensitivity to variations in oxygen concentration. Carbamylation fails to protect that population of cells which is most sensitive to the stress of severe hypoxia. The significance of these findings in relationship to human disease has not been defined, but the similarities between the behavior of cyanate-treated sickle cells in humans and in the rat suggest that this simple animal model may be of considerable value in the study of sickle cell disease and its treatment.
